No Detail Found!

Management of hepatitis B: Pakistan society for the study of liver diseases (PSSLD) practice guidelines.

Author(s)
Zaigham Abbas Department of Medicine, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Wasim Jafri Department of Medicine, the Aga Khan University Hospital, Karachi, Pakistan
Saeed Hamid Department of Medicine, the Aga Khan University Hospital, Karachi, Pakistan
Abstract
Pakistan remains in the intermediate prevalence area for Hepatitis B with an estimated carrier rate of 2.5%. Chronic Hepatitis B patients should be considered for treatment if Alanine transaminase (ALT) is persistently elevated in the last 6 months and HBV DNA is > 2000 IU/ml, irrespective of HBeAg status. In case of normal ALT and HBV DNA > 2000 IU/ml, treatment should only be considered if there is advanced fibrosis or cirrhosis on liver biopsy. HBV DNA positive cirrhotic patients should receive treatment irrespective of ALT status. Medicine available for the treatment of Hepatitis B in Pakistan are lamivudine, adefovir, telbivudine, entecavir, standard and pegylated interferon and thymosin. Patients who fail to achieve primary response as evidenced by
Publication Details
Page(s) 198-201
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 20, Issue: 3, Year: 2010

Request the full text from PASTIC

0

Citations

0

Downloads

170

Views